PMID- 19822081
OWN - NLM
STAT- MEDLINE
DCOM- 20091203
LR  - 20170214
IS  - 0394-6320 (Print)
IS  - 0394-6320 (Linking)
VI  - 22
IP  - 3
DP  - 2009 Jul-Sep
TI  - Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for dendritic 
      cell-based anti-tumor immunotherapy.
PG  - 647-58
AB  - Dendritic cells (DCs) are able to orchestrate innate and acquired immunity and 
      can activate and sustain a long-lasting anti-tumor immune response in vivo when 
      used as anti-tumor cell therapy. The selection of the antigen and the choice of 
      its formulation are key points in designing anti-cancer DC-based vaccines. Cell 
      released vesicles/exosomes have been shown to transfer antigens, HLAI/peptide 
      complexes and co-stimulatory molecules to recipient cells. In this study we 
      describe the generation of an allogenic microvesicle cell factory in which the 
      expression of a specific tumor antigen was combined to the expression of 
      co-stimulatory and allogeneic molecules. The DG75 lymphoblastoid cell line was 
      selected as microvesicle producer and transfected with ErbB2, as tumor antigen 
      prototype. The shed microvesicles transferred antigenic components to recipient 
      DCs, increasing their immunogenicity. DC pulsing resulted in cross-presentation 
      of ErbB2 both in HLAI and HLAII compartments, and ErbB2-specific CD8+ T cells 
      from cancer patients were activated by DCs pulsed with vesicle-bound ErbB2. The 
      microvesicle cell factory proposed may represent a source of cell free immunogen 
      to be used for DC-based cancer therapy.
FAU - Napoletano, C
AU  - Napoletano C
AD  - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
FAU - Rughetti, A
AU  - Rughetti A
FAU - Landi, R
AU  - Landi R
FAU - Pinto, D
AU  - Pinto D
FAU - Bellati, F
AU  - Bellati F
FAU - Rahimi, H
AU  - Rahimi H
FAU - Spinelli, G P
AU  - Spinelli GP
FAU - Pauselli, S
AU  - Pauselli S
FAU - Sale, P
AU  - Sale P
FAU - Dolo, V
AU  - Dolo V
FAU - De Lorenzo, F
AU  - De Lorenzo F
FAU - Tomao, F
AU  - Tomao F
FAU - Benedetti-Panici, P
AU  - Benedetti-Panici P
FAU - Frati, L
AU  - Frati L
FAU - Nuti, M
AU  - Nuti M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Immunopathol Pharmacol
JT  - International journal of immunopathology and pharmacology
JID - 8911335
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA Antigens)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antigens, Neoplasm/genetics/*immunology
MH  - Breast Neoplasms/immunology/*therapy
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cell Line
MH  - Dendritic Cells/immunology/*transplantation
MH  - Female
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Immunophenotyping
MH  - *Immunotherapy, Adoptive
MH  - Interferon-gamma/metabolism
MH  - *Lymphocyte Activation
MH  - Receptor, ErbB-2/genetics/*immunology
MH  - Transfection
MH  - Transport Vesicles/immunology/*transplantation
EDAT- 2009/10/14 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/10/14 06:00
PHST- 2009/10/14 06:00 [entrez]
PHST- 2009/10/14 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 10 [pii]
AID - 10.1177/039463200902200310 [doi]
PST - ppublish
SO  - Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):647-58. doi: 
      10.1177/039463200902200310.